Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Journal of Assisted Reproduction and Genetics
Erschienen in: Journal of Assisted Reproduction and Genetics 5/2013

01.05.2013 | ASSISTED REPRODUCTION TECHNOLOGIES

What is the best treatment option for infertile women aged 40 and over?

verfasst von: Sarah Armstrong, Valentine Akande

Erschienen in: Journal of Assisted Reproduction and Genetics | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To summarise the causes of decreased fecundity with age and review chronological vs biological ovarian ageing. To explore the clinician’s means of assessing a woman’s ovarian reserve. To review the recent literature on the effectiveness of different assisted reproductive technology (ART) techniques for women aged 40 and over and offer a single best treatment option.

Methods

Pubmed and google scholar were searched for relevant articles using key words. Data were extracted based on authors, year, aims, sample and results.

Results

Success rates for women aged 40 or over with clomiphene, IUI, IUI with FSH are all extremely low, at less than 1 % live birth per cycle. However, IVF offers a success rate of around 13.7 % per cycle.

Conclusion

An exploration of the effectiveness of available treatment options for older infertile women using their own gametes suggests that IVF offers the best prospects of success. Attempting treatments other than IVF will delay conception unnecessarily.
Literatur
1.
Botting B, Dunnell K. Trends in fertility and contraception in the last quarter of the 20th century. Popul Trends. 2010;100:32–9.
2.
3.
4.
Maheshwari A, Hamilton M, Bhattacharya S. Effect of female age on the diagnostic categories of infertility. Hum Reprod. 2008;23(3):538–42.PubMedCrossRef
5.
Balasch J. Investigation of the infertile couple: investigation of the infertile couple in the era of assisted reproduction technology: a time for reappraisal. Hum Reprod. 2000;15:2251–7.PubMedCrossRef
6.
Howles CM, Kim CH, Elder K. Treatment strategies in assisted reproduction for women of advanced maternal age. Int Surg. 2006;91(5 Suppl):S37–54.PubMed
7.
8.
ESHRE Capri Workshop Group. Fertility and ageing. Hum Reprod Updat. 2005;11:261–76.CrossRef
9.
Kline J, Stein Z, Susser M. Conception to birth. New York: Oxford University Press; 1989. p. 259–94.
10.
Marcus S, Brinsden P. In-vitro fertilization and embryo transfer in women aged 40 years and over. Hum Reprod Updat. 1996;2(6):459–68.CrossRef
11.
Magarelli C, Pearlstone C, Buyalos R. Discrimination between chronological and ovarian age in infertile women aged 35 years and older: predicting pregnancy using basal follicle stimulating hormone, age and number of ovulation induction/intra-uterine insemination cycles. Hum Reprod. 1996;11(6):1214–9.PubMedCrossRef
12.
Lobo RA. Early ovarian ageing: a hypothesis. What is early ovarian ageing? Hum Reprod. 2003;18:1762–4.PubMedCrossRef
13.
Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod. 1992;7:1342–6.PubMed
14.
Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, Klein NA. A new model of reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause. Hum Reprod. 2008;23:699–708.PubMedCrossRef
15.
Johnson NP, Bagrie EM, Coomarasamy A, Bhattacharya S, Shelling AN, Jessop S. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. BJOG. 2006;113:1472–80.PubMedCrossRef
16.
Navot D, Bergh PA, Williams MA, et al. Poor oocyte quality rather than implantation failure as a cause of age-related decline in female fertility. Lancet. 1991;337:1375–7.PubMedCrossRef
17.
Akande VA, Fleming CF, Hunt LP, Keay SD, Jenkins JM. Biological versus chronological ageing of oocytes, distinguishable by raised FSH levels in relation to the success of IVF treatment. Hum Reprod. 2002;17(8):101–6.CrossRef
18.
Alviggi C, Humaidan P, Howles CM, Tredway D, Hillier SG. Biological versus chronological ovarian age: implications for assisted reproductive technology. Reprod Biol Endocrinol. 2009;7:101.PubMedCrossRef
19.
Scott RT et al. Follicle stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril. 1989;51:651–4.PubMed
20.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Updat. 2006;12:685–718.CrossRef
21.
Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod. 2007;22:2414–21.PubMedCrossRef
22.
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artensio AC, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Updat. 2010;16:113–30.CrossRef
23.
Kelsey TW, Anderson RA, Wright P, Nelson SM, Wallace WHB. Data-driven assessment of the human ovarian reserve. Mol Hum Reprod. 2012;18(2):79–87.PubMedCrossRef
24.
Bhide P, Gudi A, Shah A, Timms P, Grayson K, Homburg R. Anti-Mullerian hormone as a predictor of pregnancy following IVF. Reprod BioMed Online. 2013;26:247–52.PubMedCrossRef
25.
Tsafrir A, Simon A, Margalioth E, Laufer N. What should be the first-line treatment for unexplained fertility in women over 40 years of age—ovulation induction and IUI or IVF? Reprod BioMed Online; www.​rbmonline.​com/​Article/​4334 on web 15 Sept 2009.
26.
Guzick DS, Sullivan MW, Adamson GD. Efficacy of treatment for unexplained fertility. Fertil Steril. 1998;70:207–13.PubMedCrossRef
27.
Bhattacharya S, Harrild K, Mollison J. Clomifene citrate or unstimulated intrauterine insemination compared with expectant management for unexplained infertility: pragmatic randomized controlled trial. Br Med J. 2008;337:716.CrossRef
28.
Corsan G, Trias A, Trout S, Kemmann E. Ovulation induction combined with intrauterine insemination in women 40 years of age and older: is it worthwhile? Hum Reprod. 1996;11(5):1109–12.PubMedCrossRef
29.
Dovey S, Sneeringer R, Penzias A. Clomiphene citrate and intrauterine insemination: analysis of more than 4100 cycles. Fertil Steril. 2008;90(6):2281–6.PubMedCrossRef
30.
Liu K, Case A, Saskatoon SK. Advancing reproductive age and fertility. Int J Gynaecol Obstet. 2011;117:95–102.CrossRef
31.
Haebe J, Martin J, Tekepety F, Tummon I, Shepherd K. Success of intrauterine insemination in women aged 40–42 years. Fertil Steril. 2002;78(1):29–33.PubMedCrossRef
32.
Merviel P, Heraud MH, Grenier N, Lourdel E, Sanguinet P, Copin H. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. Fertil Steril. 2010;93(1):79–88.PubMedCrossRef
33.
Andersen et al. Assisted reproductive technology in Europe, 2004: results generated from European registers by ESHRE. Hum Reprod. 2008;23(4):756–71.PubMedCrossRef
34.
Pandian Z, Gibreel AF, Bhattacharya S. In-vitro fertilization for unexplained subfertilty. Cochrane Libr 2010; Issuee 11.
35.
Nyboe et al. Assisted Reproductive technology and intrauterine inseminations in Europe 2005: results generated from European registers by ESHRE. Hum Reprod. 2009;24:1267–87.CrossRef
36.
ESHRE Capri workshop group 2009. Intrauterine insemination. Hum Reprod Updat. 2009;15:265–77.CrossRef
37.
38.
Moragianni V, Penzias A. Cumulative live-birth rates after assisted reproductive technology. Curr Opin Obstet Gynecol. 2010;22:189–92.PubMedCrossRef
39.
Wiser A et al. Ovarian stimulation and intrauterine insemination in women aged 40 years or more. Reprod BioMed Online. 2012;24:170–3.PubMedCrossRef
Metadaten
Titel
What is the best treatment option for infertile women aged 40 and over?
verfasst von
Sarah Armstrong
Valentine Akande
Publikationsdatum
01.05.2013
Verlag
Springer US
Erschienen in
Journal of Assisted Reproduction and Genetics / Ausgabe 5/2013
Print ISSN: 1058-0468
Elektronische ISSN: 1573-7330
DOI
https://doi.org/10.1007/s10815-013-9980-6

Weitere Artikel der Ausgabe 5/2013

Journal of Assisted Reproduction and Genetics 5/2013 Zur Ausgabe

Genetics

Mannose binding lectin genotypes are not associated with increased risk of unexplained recurrent pregnancy loss

ASSISTED REPRODUCTION TECHNOLOGIES

The predictive value of anti-mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET)

Genetics

Association study between FSHR Ala307Thr and Ser680Asn variants and polycystic ovary syndrome (PCOS) in Northern Chinese Han women

Embryo Biology

Chromosomal integrity of human preimplantation embryos at different days post fertilization

ASSISTED REPRODUCTION TECHNOLOGIES

Polar body fragmentation in IVM oocytes is associated with impaired fertilization and embryo development

Technological Innovations

A novel approach to quantifying ovarian cell lipid content and lipid accumulation in vitro by confocal microscopy in lean women undergoing ovarian stimulation for in vitro fertilization (IVF)

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise